China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. China Resources Sanjiu Medical & Pharmaceutical Co., Ltd.

China Resources Sanjiu Medical & Pharmaceutical Co., Ltd.

000999

Clasificación en acciones #2914
China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. is a prominent... China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. is a prominent pharmaceutical enterprise engaged in the research, development, manufacturing, and distribution of medicinal products. Its operations span both the People's Republic of China and international markets, additionally providing various health-related services. The company's extensive product line includes a wide range of over-the-counter (OTC) medications addressing common conditions such as colds, skin issues, gastrointestinal complaints, coughs, and needs in orthopedics and pediatrics. It also provides prescription drugs, with a focus on areas like traditional Chinese medicine, oncology, cardiovascular and cerebrovascular health, digestive system disorders, orthopedics, and pediatrics. Further offerings comprise Chinese medicine injections, specialized formula granules, and anti-infective agents. These products are often marketed under popular brand families, notably 999 family medicine, Sanjiuweitai series, 999 Ganmaoling series, and 999 dermatitis series. Founded in 1999 and headquartered in Shenzhen, PRC, the company initially operated as Sanjiu Pharmaceutical Co., Ltd. before rebranding to its current name in February 2010. It functions as a subsidiary under the umbrella of China Resources (Holdings) Co., Ltd.
Precio por acción
$3.74
Capitalización bursátil
$6.23B
Cambio (1 día)
-2.11%
Cambio (1 año)
-8.54%
País
CN
Comercio China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. (000999)

Categoría

Healthcare
Ingresos de China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. (000999)
Ingresos en Jun 2026 TTM: $4.76B
Según los últimos informes financieros de China Resources Sanjiu Medical & Pharmaceutical Co., Ltd., los ingresos actuales de la empresa (TTM) son $4.76B. En 2024, la empresa obtuvo unos ingresos de $3.78B un aumento con respecto a los ingresos del año 2023, que fueron de $3.49B. Los ingresos representan la cantidad total que una empresa genera por la venta de bienes o servicios. A diferencia de las ganancias, no se restan los gastos.
Historial de ingresos de China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. desde 2001 hasta 2026
Ingresos al final de cada año
Año Ingresos Cambiar
2026 (TTM) $4.76B 5.44%
2025 $4.52B 19.38%
2024 $3.78B 8.26%
2023 $3.49B 42.90%
2022 $2.45B 17.16%
2020 $2.09B -1.74%
2019 $2.12B 8.83%
2018 $1.95B 14.22%
2017 $1.71B 32.12%
2016 $1.29B 6.34%
2015 $1.22B 3.56%
2014 $1.17B -2.29%
2013 $1.20B 7.98%
2012 $1.11B 28.69%
2011 $865.22M 30.83%
2010 $661.34M -6.96%
2009 $710.79M 12.37%
2008 $632.54M 35.93%
2007 $465.35M 26.67%
2006 $367.39M -0.13%
2005 $367.88M 23.67%
2004 $297.46M -7.95%
2003 $323.17M 23.51%
2002 $261.66M 15.95%
2001 $225.66M 0.00%
Ingresos de empresas similares o competidoras
Empresa Ingresos Diferencia de ingresos País
$23.54B 394.15%
DE
$23.73B 398.34%
DE
$29.24B 513.92%
JP
$5.85B 22.80%
CH
$6.34B 33.16%
IN